Skip to main content
. 2017 Dec 8;9(1):1041–1047. doi: 10.18632/oncotarget.23133

Figure 5. In vivo validation of alsterpaullone-mediated chemoresistance reversal.

Figure 5

Immunohistochemical analysis of molecular markers in control, paclitaxel-treated, and alsterpaullone-pretreated tumors. Representative images of tumors in each treatment group. PTX, paclitaxel; AP, alsterpaullone.*,p < 0.05;**, p < 0.01.